HELENE Clinic

Name

HELENE Clinic

Legal name

表参道ヘレネクリニック (Omotesando HELENE CLINIC)

Website

https://stemcells.jp

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Regenerative Medicine Services

NAICS

Offices of Physicians (62111), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Developers (Autologous) (HLAAABAA)

akta.pro secondary industries

Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC), Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH)

Keywords

• Stem cell therapy
• Regenerative medicine
• Cell therapy services
• Medical tourism clinics
• Cancer screening diagnostics

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices5 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Stem Cell Therapy Treatment: Self-pay medical treatment fees varying by cell count. Treatment involves extraction of patient's own adipose tissue, 4-week cultivation period, and administration via IV drip or subcutaneous injection. Core revenue stream with treatment pricing based on cell quantity delivered.
2. MSC Exosome Products: Sale of umbilical cord-derived MSC exosome liquid products for various administration methods (inhalation, topical application, subcutaneous injection, IV, intramuscular). 臍帯幹細胞由来エクソソーム液プロセンタン at 280,000 JPY per 10-vial box.
3. Supernatant Treatment: Stem cell culture supernatant therapy containing cytokines and growth factors. Administered via IV drip for approximately 40-60 minutes at 165,000 JPY.
4. Proteo Cancer Screening: Early cancer risk detection test using proprietary proteo chip technology. Blood test at 200,000 JPY for inspection and testing fees.
5. COVID-19 PCR Testing: Self-pay PCR testing services for travel purposes. 25,000 JPY for saliva PCR test with negative certificate issuance.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

HELENE Clinic provides self-pay autologous mesenchymal stem cell (MSC) therapy by harvesting a patient's own cells, culturing them to up to 22.5 billion cells over approximately four weeks using a proprietary animal-origin-free HELENE Medium, and administering them via IV drip or local injection. It also offers MSC exosome therapy, stem cell culture supernatant therapy, Proteo proteomics-based cancer risk screening, brown adipose tissue injection for metabolic restoration, and the HELENE Cosme at-home stem cell extract skincare line. Treatments target anti-aging, diabetes, cardiovascular disease, osteoarthritis, neurodegenerative conditions, and other regenerative medicine indications for both domestic Japanese and international medical tourism patients.

Product overview

HELENE Clinic is a regenerative medicine clinic offering stem cell and exosome-based therapies. The core offerings include autologous adipose-derived MSC therapy (culturing patient's own stem cells to up to 22.5 billion cells for IV/subcutaneous administration), MSC exosome therapy (for signal transduction and inflammation reduction), and culture supernatant therapy (for skin regeneration and anti-aging). Supporting products include Protéo cancer risk screening for ultra-early cancer detection, brown adipose tissue injection for metabolic restoration, and HELENE Cosme skincare line for home use. The clinic also provides multilingual AI support via the Helene-sensei voice assistant and educational VR content for exosome treatment understanding.

Differentiator

Problem solved

Functional benefit

Brands

• HELENE Medium: Proprietary animal-origin-free, serum-free culture medium (AOF) developed for mesenchymal stem cell cultivation, presented at the Cambridge International Stem Cell Symposium in 2018.
• MSC Exosome Treatment
• PROTEO (Proteomics Cancer Screening)
• Stem Cell Supernatant (培養上清液)
• AI Doctor – Helene-sensei (AI音声アシスタント)

Products and services

• Stem Cell Therapy (MSC Treatment) Autologous adipose-derived mesenchymal stem cell therapy where the patient's own cells are harvested, cultured for approximately four weeks to up to 22.5 billion cells using proprietary HELENE Medium, and administered via intravenous drip, subcutaneous injection, or local injection for regenerative treatment of anti-aging, diabetes, cardiovascular disease, osteoarthritis, and other conditions.
• MSC Exosome Therapy (Procyotan Exosome Product) Treatment using exosomes (≤100nm vesicles) derived from mesenchymal stem cells, administered via inhalation, topical application, subcutaneous injection, intravenous drip, or intramuscular injection. Priced at 280,000 JPY per 10-vial box.
• Culture Supernatant Therapy (Stem Cell Supernatant) Treatment using stem cell culture supernatant liquid containing over 500 types of proteins, cytokines, and growth factors (including EGF, TGF-α, TGF-β, PDGF, VEGF, IGF-I), administered via IV drip (40–60 minutes) for skin regeneration and anti-aging effects. Priced at 165,000 JPY (tax included).
• Protéo Cancer Risk Screening Ultra-early cancer risk detection test using proteomics technology. A 30-microliter blood sample is analyzed via fluorescent microscopy to detect cancer-associated substances, identifying risk levels A/B/C for solid tumors including lung, breast, stomach, liver, colon, tongue, thyroid, kidney, prostate, uterine, and ovarian cancers. Priced at 200,000 JPY (tax included) with a reported 95.4% 5-year survival rate for Stage I detection.
• Brown Adipose Tissue Injection Injection treatment targeting brown fat cells near the collarbone to increase basal metabolism and restore metabolic rate to levels comparable to those in one's twenties, addressing age-related metabolic decline and obesity.
• HELENE Cosme (Stem Cell Extract Skincare) At-home concentrated human stem cell extract skincare product line developed from the clinic's stem cell technology expertise and customer feedback from the aesthetic industry. Sold via dedicated Shopify e-commerce storefront.
• COVID-19 PCR Testing Self-pay saliva PCR testing service with negative certificate issuance for travel purposes. Priced at 25,000 JPY per test (tax excluded), with volume discounts available (10-test package at 200,000 JPY; corporate discounts starting at 22,000 JPY/person for 5+ persons down to 12,000 JPY/person for 100+ persons).

Quantifiable outcome

• 10-year MACCE (major adverse cardiac/cerebrovascular events) rate reduced to approximately 1/3 in high-dose (1 billion) MSC group vs low-dose (100-300 million) group
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

Six partnerships are on record, tiered core and moderate.

• Cambridge University - Professor Ravindra GuptacoreStrategic or Co-development PartnerScientific advisory relationship with Cambridge University Professor Ravindra Gupta (clinical microbiology). Professor Gupta provides validation of HELENE Clinic's MSC cultivation technology and exosome research. Featured in promotional interviews endorsing clinic's quality standards and 22.5 billion MSC cultivation achievement.
• American Board of Regenerative Medicine (ABRM)coreStrategic or Co-development PartnerExclusive ABRM certification agency designation for Japan region. HELENE Clinic organizes ABRM intensive courses and examinations for physicians seeking certification in Japan. Dr. Rozina Badal Munir visited clinic to review facilities and sign partnership contract February 2024.
• Takara Bio Inc.moderateTechnology or IntegrationThird-party reagent company providing quality verification for stem cell products. Cells cultured at HELENE labs are sent to Takara Bio for independent testing as part of triple quality verification process. Testing includes sterility, mycoplasma, endotoxin, and tumorogenicity assays.
• 3rd MENA Stem Cell Forum (Dubai)moderateGTM or Marketing PartnerInternational stem cell conference where HELENE Clinic's Dr. Hara served as panel speaker in June 2024. Represents clinic's presence and reputation in Middle East market.
• Medical Tourism Coordination AgenciescoreChannel Partner/ Reseller/ DistributorNetwork of 20+ international medical tourism agencies facilitating patient intake from China, Vietnam, and other countries. Includes Japan Medical Interpreter Center (J-MTC), Aoyama Meijo, Yin Yo, Bankouda, Medical Beauty Japan, and others.
• STEMCELL Co. (関連会社)moderateStrategic or Co-development PartnerAffiliate company collaborating on VR content development for exosome treatment education. Released multilingual VR video explaining treatment concepts in collaboration with HELENE Clinic.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Others

• Lonza Cell & Gene Technologies: Global contract development and manufacturing organization for cell and gene therapies, including autologous and allogeneic cell therapy manufacturing services. Adjacent ecosystem participant providing biomanufacturing infrastructure that HELENE's in-house CPC competes with or could partner with for scale-out.
• Takara Bio: Japanese cell and gene therapy tools/CDMO provider and HELENE's third-party quality verification partner for stem cell products. Adjacent industry participant supplying reagents, testing, and bioprocessing infrastructure that supports HELENE's cell therapy operations.

Direct peers

• Swiss Medica: Stem cell therapy clinics operating in Serbia and Russia providing autologous MSC treatments to international medical tourism patients. Comparable self-pay regenerative medicine positioning and treatment portfolio targeting chronic and age-related conditions.
• Celltex Therapeutics: US-headquartered autologous MSC therapy provider with Mexico clinic operations, focused on banking and therapeutic use of adult mesenchymal stem cells. Targets similar affluent, chronic-condition patients seeking regenerative treatments outside mainstream FDA-approved channels.
• Regenexx: US-based regenerative medicine network offering autologous stem cell and platelet-rich plasma treatments, primarily for orthopedic and musculoskeletal conditions. Comparable autologous cell therapy clinic model and self-pay positioning in the regenerative medicine category.
• Dr. Stem Cells Tokyo / Japan Regenerative Medicine Clinics: Japan-based competitor operating under the MHLW Regenerative Medicine Safety Act framework, offering autologous stem cell therapies to both domestic and international patients. Closely comparable regulatory and clinical positioning to HELENE within the Japanese market.
• Stem Cell Institute (MediStem Panama): Panama-based regenerative medicine clinic offering autologous stem cell therapy primarily to international medical tourism patients, with similar self-pay model and treatment portfolio (anti-aging, chronic disease, orthopedic). Closely comparable to HELENE in patient profile and self-pay medical tourism positioning.
• Giostar (Global Institute of Stem Cell Therapy): Multi-country stem cell clinic network (Mexico, India) offering autologous and allogeneic MSC therapies for medical tourism patients. Closely mirrors HELENE's international hub strategy and self-pay regenerative medicine offering, including anti-aging and chronic disease indications.

Broad incumbents

• Mesoblast: Publicly-traded Australian allogeneic MSC platform company developing off-the-shelf cellular medicines for inflammatory and cardiovascular diseases. Larger, established player operating broadly in regenerative medicine with overlapping MSC technology but a fundamentally different allogeneic, regulated-drug business model vs HELENE's autologous clinical services.
• Pluristem Therapeutics: Publicly-traded cell therapy company developing allogeneic placenta-derived MSC products for multiple indications including muscle injury and hematopoietic recovery. Larger, established regenerative medicine company with overlapping MSC category but operates in regulated drug development rather than clinical service delivery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/helene-clinic

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HELENE Clinic